Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Mutations in the gene are detectable in approximately 40% of -rearranged lung cancers resistant to ALK inhibitors. Although epithelial-to-mesenchymal transition (EMT) is a mechanism of resistance to various targeted drugs, its involvement in ALK inhibitor resistance is largely unknown. In this study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2019-04, Vol.79 (7), p.1658-1670
Hauptverfasser:	Fukuda, Koji, Takeuchi, Shinji, Arai, Sachiko, Katayama, Ryohei, Nanjo, Shigeki, Tanimoto, Azusa, Nishiyama, Akihiro, Nakagawa, Takayuki, Taniguchi, Hirokazu, Suzuki, Takeshi, Yamada, Tadaaki, Nishihara, Hiroshi, Ninomiya, Hironori, Ishikawa, Yuichi, Baba, Satoko, Takeuchi, Kengo, Horiike, Atsushi, Yanagitani, Noriko, Nishio, Makoto, Yano, Seiji
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaplastic Lymphoma Kinase - antagonists & inhibitors Anaplastic Lymphoma Kinase - genetics Carbazoles - pharmacology Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Crizotinib - pharmacology Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition - drug effects Histone Deacetylase Inhibitors - pharmacology Humans Hydroxamic Acids - pharmacology Lung Neoplasms - enzymology Lung Neoplasms - pathology MicroRNAs - genetics Mutation Piperidines - pharmacology Protein Kinase Inhibitors - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!